Tobacco Wholesaler Sentenced for Violating PACT Act

Aug.12.2022
Tobacco wholesaler in Massachusetts sentenced to probation for violating PACT Act. Assets worth $2,197,985 seized.

A tobacco wholesaler from Connecticut was sentenced today in federal court in Springfield, Massachusetts for violating the Prevent All Cigarette Trafficking (PACT) Act.


Syed I. Bokhari, 57, was granted one year probation by U.S. District Court Judge Mark G. Mastroianni. The government had recommended an 18-month prison sentence. Bokhari pleaded guilty on April 19, 2022. In a related civil forfeiture suit, Bokhari agreed to forfeit seized tobacco, currency, and other assets, resulting in the government reclaiming $2,197,985.


The PACT Act was established in 2010 to prevent the imposition of tobacco taxes by the government on cigarettes and smokeless tobacco. Among other things, the PACT Act requires businesses to submit a statement to the state tobacco tax administrator before shipping cigarettes or smokeless tobacco into the state.


Bokhari owns and operates a wholesale supply business in Scranton, Pennsylvania, selling smokeless tobacco to customers in Massachusetts. Between 2010 and June 5, 2012, Bokhari's business shipped smokeless tobacco to customers in Massachusetts but failed to submit the required declarations to the Massachusetts Department of Revenue.


Rachel S. Rollins, U.S. Attorney; Geoffrey E. Snyder, Commissioner of the Massachusetts Department of Revenue; Joleen D. Simpson, Special Agent in charge of criminal investigations at the Boston office of the U.S. Internal Revenue Service; James M. Ferguson, Special Agent in the Boston Field Division of the Bureau of Alcohol, Tobacco, Firearms and Explosives; and Special Agent Matthew Milholland, in charge of Homeland Security Investigations in Boston, announced this news. The Assistant U.S. Attorney Christopher L. Morgan at the Springfield branch of the Rollins office filed the case.


Statement:


This article has been compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is only intended for communication and research within the industry.


As the translation is limited by the proficiency of the translator, the translated article may not fully convey the same meaning as the original article. Therefore, please refer to the original article for accuracy.


2FIRSTS maintains full alignment with the Chinese government on matters of domestic policy, as well as issues involving Hong Kong, Macau, Taiwan, and foreign relations.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

JTI UK Expands Nordic Spirit Line, Launches 17mg Nicotine Pouch
JTI UK Expands Nordic Spirit Line, Launches 17mg Nicotine Pouch
JTI UK has launched Nordic Spirit’s highest-strength variant—Frosty Mint Max, delivering 17mg of nicotine per pouch—and introduced a refreshed, darker packaging design for the brand.
Oct.31 by 2FIRSTS.ai
BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%
BAT Korea Announces Fall Promotion for glo™ hyper Series, Price Reductions up to 40%
BAT Rothmans introduces "glo hyper" series promotion in South Korea, with "glo hyper pro" for $20 and "glo hyper" for $14.
Oct.15 by 2FIRSTS.ai
KT&G to Complete New Indonesian Factory, Its Largest Overseas Production Hub
KT&G to Complete New Indonesian Factory, Its Largest Overseas Production Hub
According to Daily Hankooki, KT&G’s new factory in Indonesia will be completed this month and is scheduled to begin operations in February 2026. Once operational, the facility will have an annual production capacity of around 35 billion cigarettes, becoming the company’s largest overseas manufacturing base.
Nov.12 by 2FIRSTS.ai
Kyrgyzstan considers six-month ban on e-cigarette and e-cigarettee-liquid imports
Kyrgyzstan considers six-month ban on e-cigarette and e-cigarettee-liquid imports
According to Kyrgyz media, the Ministry of Economy and Commerce has launched a public discussion on a draft decree proposing a six-month ban on the import of e-cigarettes and nicotine-containing liquids. The measure, based on Article 15-1 of the Law “On Protecting Citizens’ Health from the Consequences of Tobacco and Nicotine Use,” aims to safeguard public health and prevent youth nicotine addiction.
Nov.12 by 2FIRSTS.ai
Ohio Appeals Court Upholds Dismissal of Lawsuit Against E-Cigarette Retailer, Deepening State-Federal Regulatory Dispute
Ohio Appeals Court Upholds Dismissal of Lawsuit Against E-Cigarette Retailer, Deepening State-Federal Regulatory Dispute
Ohio Appeals Court Rejects State Attorney General's Lawsuit Against E-Cigarette Retailer, Emphasizing FDA Regulatory Authority.
Oct.15 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai